Apollo Therapeutics and The Institute of Cancer Research enter into collaboration for cancer drug development

ICR joins UCL, University of Cambridge, Imperial College London and King’s College London as a strategic partner; Apollo continues focus on accessing the world’s best science.

Apollo Therapeutics (‘Apollo’), a portfolio biopharmaceutical company focusing on translational biology and drug development, and The Institute of Cancer Research, London, a world-leading cancer research organisation, announce they have entered into a strategic collaboration to discover and develop new cancer medicines. The collaboration combines the strengths and resources of both organisations to bring forward the development of novel therapies for cancer patients worldwide.

Apollo’s translational scientists and drug development specialists, who are already developing a diverse portfolio of over 20 therapeutic programs, will work with the ICR on research programs to rapidly and efficiently progress those with the greatest promise through preclinical and clinical development and ultimately to patients globally.

Read the full story here.

Related Content

We make UCL’s research physical and life sciences ideas happen.